Physician profile
David A Reichstein
NPI 1669665105
$114,417.36
in general payments reported to CMS, 2019-2025
23 companies · $36K in 2025
The $36K reported for 2025 was more than what 96% of Retina Specialist providers received nationally (typical 2025 total: $460).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $25K · 2020: $6,658 · 2021: $3,695 · 2022: $23K · 2023: $18K · 2024: $2,805 · 2025: $36K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $34K · Consulting Fee: $8,565 · Food and Beverage: $8,037 · Travel and Lodging: $5,618 · Honoraria: $400.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $33,583.80 |
| Consulting Fee | $8,565.00 |
| Food and Beverage | $8,037.35 |
| Travel and Lodging | $5,618.40 |
| Honoraria | $400.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $50,776.99 | 2019-2025 | Vabysmo, Susvimo, Lucentis |
| Regeneron Healthcare Solutions, INC. | $32,780.66 | 2019-2025 | Eylea Hd, Eylea |
| US Retina LLC | $16,764.16 | 2019-2022 | |
| Carl Zeiss Meditec, INC. | $4,000.00 | 2019 | |
| Immunocore Limited | $3,867.66 | 2022-2025 | Kimmtrak |
| Alimera Sciences, INC. | $2,565.21 | 2019-2024 | Iluvien, Yutiq |
| Regeneron Pharmaceuticals, INC. | $452.61 | 2019-2024 | Eylea, Eylea Hd |
| Genentech, INC. | $410.39 | 2019-2025 | Vabysmo, Susvimo |
| Harrow Eye, LLC | $401.20 | 2024-2025 | Triesence, Iheezo |
| Astellas Pharma US INC | $370.23 | 2023-2025 | Izervay |
| Alcon Vision LLC | $348.95 | 2019-2025 | Ngenuity, Constellation |
| Abbvie INC. | $334.08 | 2023-2025 | |
| Delcath Systems | $277.37 | 2024-2025 | Hepzato Kit |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $232.55 | 2019-2021 | |
| Apellis Pharmaceuticals, INC. | $204.05 | 2023-2025 | Syfovre |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coherus Oncology, INC. | $198.41 | 2022-2024 | |
| Biogen, INC. | $161.46 | 2022-2024 | Byooviz |
| Allergan, INC. | $118.12 | 2019 | |
| Novartis Pharmaceuticals Corporation | $106.32 | 2019-2020 | |
| Amgen INC. | $24.45 | 2025 | Pavblu |
| Ani Pharmaceuticals, INC. | $22.49 | 2025 | Iluvien |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$57,142.84 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Reichstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.